Sorafenib overcomes irinotecan resistance in colorectal cancer by inhibiting the ABCG2 drug-efflux pump

Molecular Cancer Therapeutics

Volumn 12, Issue 10, 2013, Pages 2121-2134

  Mazard, Thibault ^a   Causse, Annick ^b   Simony, Joelle ^c   Leconet, Wilhem ^b   Vezzio Vie, Nadia ^b   Torro, Adeline ^b   Jarlier, Marta ^c   Evrard, Alexandre ^d   Rio, Maguy Del ^b   Assenat, Eric ^a   Martineau, Pierre ^b   Ychou, Marc ^c   Robert, Bruno ^b   Gongora, Celine ^b  

^a Medical Oncology Unit   (France)

^b INSTITUT DE RECHERCHE EN CANCÉROLOGIE DE MONTPELLIER   (France)

^c CENTRE VAL D AURELLE   (France)

^d NÎMES UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; FIRTECAN; IRINOTECAN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; SORAFENIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; COLORECTAL CANCER; CONTROLLED STUDY; DRUG EFFICACY; DRUG TARGETING; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; GENE EXPRESSION REGULATION, NEOPLASTIC; HCT116 CELLS; HUMANS; MICE; NEOPLASM PROTEINS; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84885607372     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-12-0966     Document Type: Article

References (42)

1. Ferlay J, Shin H-R, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008:GLOBOCAN2008. Int J Cancer 2010;127: 2893-917.
2. Van Cutsem E, Nordlinger B, Cervantes A. Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment. Ann Oncol 2010;21 Suppl 5:v93-97.
3. Pommier Y. Camptothecins and topoisomerase I: a foot in the door. Targeting the genome beyond topoisomerase I with camptothecins and novel anticancer drugs: importance of DNA replication, repair and cell cycle checkpoints. Curr Med Chem Anticancer Agents 2004;4: 429-34.
4. Pommier Y, Leo E, Zhang H, Marchand C. DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem Biol 2010;17: 421-33.
5. Pommier Y. DNA topoisomerase I inhibitors: chemistry, biology, and interfacial inhibition. Chem Rev 2009;109: 2894-902.
6. Pommier Y, Pourquier P, Urasaki Y, Wu J, Laco GS. Topoisomerase I inhibitors: selectivity and cellular resistance. Drug Resist Updat 1999; 2: 307-18.
7. Gongora C, Vezzio-Vie N, Tuduri S, Denis V, Causse A, Auzanneau C, et al. New Topoisomerase I mutations are associated with resistance to camptothecin. Mol Cancer 2011;10: 64-77.
8. Xu Y, Villalona-Calero MA. Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity. Ann Oncol 2002;13: 1841-51.
9. Paillas S, Boissière F, Bibeau F, Denouel A, Mollevi C, Causse A, et al. Targeting the p38 MAPK pathway inhibits irinotecan resistance in colon adenocarcinoma. Cancer Res 2011;71: 1041-9.
10. Maliepaard M, Van Gastelen MA, De Jong LA, Pluim D, Van Waardenburg RC, Ruevekamp-Helmers MC, et al. Overexpression of theBCRP/ MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res 1999;59: 4559-63.
11. Brangi M, Litman T, Ciotti M, Nishiyama K, Kohlhagen G, Takimoto C, et al. Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells. Cancer Res 1999;59: 5938-46.
12. Candeil L, Gourdier I, Peyron D, Vezzio N, Copois V, Bibeau F, et al. ABCG2 overexpression in colon cancer cells resistant to SN38 and in irinotecan-treated metastases. Int J Cancer 2004;109: 848-54.
13. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan- refractory metastatic colorectal cancer. NEngl J Med 2004;351: 337-45.
14. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26: 1626-34.
15. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359: 1757-65.
16. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 2008;7: 3129-40.
17. Escudier B, Eisen T, StadlerWM,Szczylik C, Oudard S, Siebels M, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356: 125-34.
18. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J-F, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-90.
19. Beeram M, Patnaik A, Rowinsky EK. Raf: a strategic target for therapeutic development against cancer. J Clin Oncol 2005;23: 6771-90.
20. Wei Y, Ma Y, Zhao Q, Ren Z, Li Y, Hou T, et al. New Use for an Old Drug: Inhibiting ABCG2 with Sorafenib. Mol Cancer Ther 2012;11: 1693-702.
21. Chou T-C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006;58: 621-81.
22. Chou T-C. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 2010;70: 440-6.
23. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64: 7099-109.
24. Martinelli E, Troiani T, Morgillo F, Rodolico G, Vitagliano D, Morelli MP, et al. Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells. Clin Cancer Res 2010;16: 4990-5001.
25. Awada A, Hendlisz A, Gil T, Bartholomeus S, Mano M, De Valeriola D, et al. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer 2005;92: 1855-61.
26. Clark JW, Eder JP, Ryan D, Lathia C, Lenz H-J. Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res 2005;11: 5472-80.
27. Moore M, Hirte HW, Siu L, Oza A, Hotte SJ, Petrenciuc O, et al. Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase andVEGFRinhibitorBAY43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Ann Oncol 2005;16: 1688-94.
28. Strumberg D, Richly H, Hilger RA, Schleucher N, Korfee S, Tewes M, et al. Phase I clinical and pharmacokinetic study of theNovel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005; 23: 965-72.
29. Mross K, Steinbild S, Baas F, Gmehling D, Radtke M, Voliotis D, et al. Results from an in vitro and a clinical/pharmacological phase I study with the combination irinotecan and sorafenib. Eur J Cancer 2007;43: 55-63.
30. Azad N, Dasari A, Arcaroli J, Taylor GE, Laheru DA, Carducci MA, et al. Phase I pharmacokinetic and pharmacodynamic study of cetuximab, irinotecan and sorafenib in advanced colorectal cancer. Invest New Drugs 2012;31: 345-54.
31. Hu S, Chen Z, Franke R, Orwick S, Zhao M, Rudek MA, et al. Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters. Clin Cancer Res 2009;15: 6062-9.
32. Carloni S, Fabbri F, Brigliadori G, Ulivi P, Silvestrini R, Amadori D, et al. Tyrosine kinase inhibitors gefitinib, lapatinib and sorafenib induce rapid functional alterations in breast cancer cells. Curr Cancer Drug Targets 2010;10: 422-31.
33. Mogi M, Yang J, Lambert J-F, Colvin GA, Shiojima I, Skurk C, et al. Akt signaling regulates side population cell phenotype via Bcrp1 translocation. J Biol Chem 2003;278: 39068-75.
34. Ding X, Wu J, Jiang C. ABCG2: a potential marker of stem cells and novel target in stem cell and cancer therapy. Life Sci 2010;86: 631-7.
35. Fang DD, Kim YJ, Lee CN, Aggarwal S, McKinnon K, Mesmer D, et al. Expansion of CD133(+) colon cancer cultures retaining stem cell properties to enable cancer stem cell target discovery. Br J Cancer 2010;102: 1265-75.
36. Jayanthan A, Bernoux D, Bose P, Riabowol K, Narendran A. Multityrosine kinase inhibitors in preclinical studies for pediatric CNS AT/ RT: evidence for synergy with Topoisomerase-I inhibition. Cancer Cell Int 2011;11: 44-55.
37. Peer CJ, Sissung TM, Kim A, Jain L, Woo S, Gardner ER, et al. Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemia. Clin Cancer Res 2012;18: 2099-107.
38. Cummings J, Ethell BT, Jardine L, Boyd G, Macpherson JS, Burchell B, et al. Glucuronidation as a mechanism of intrinsic drug resistance in human colon cancer: reversal of resistance by food additives. Cancer Res 2003;63: 8443-50.
39. Namboodiri HV, Bukhtiyarova M, Ramcharan J, Karpusas M, Lee Y, Springman EB. Analysis of imatinib and sorafenib binding to p38alpha compared with c-Abl and b-Raf provides structural insights for understanding the selectivity of inhibitors targeting the DFG-out form of protein kinases. Biochemistry 2010;49: 3611-8.
40. Grossi V, Liuzzi M, Murzilli S, Martelli N, Napoli A, Ingravallo G, et al. Sorafenib inhibits p38a activity in colorectal cancer cells and synergizes with the DFG-in inhibitor SB202190 to increase apoptotic response. Cancer Biol Ther 2012;13: 1471-81.
41. McDaid HM, Lopez-Barcons L, Grossman A, Lia M, Keller S, Ṕerez- Soler R, et al. Enhancement of the therapeutic efficacy of taxol by the mitogen-activated protein kinase kinase inhibitor CI-1040 in nude mice bearing human heterotransplants. Cancer Res 2005;65: 2854-60.
42. Ychou M, Bouche O, Thezenas S, Francois E, Adenis A, Bennouna J, et al. Final results of a multicenter phase II trial assessing sorafenib (S) in combination with irinotecan (i) as second- or later-line treatment in metastatic colorectal cancer (mCRC) patients (pts) with KRASmutated tumors (mt; NEXIRI). J Clin Oncol 29:15s, 2011 (suppl; abstr e14002).